Levy Guy
Known title: 10% OwnerCIK: 0001812305
Levy Guy's purchase track record
Levy Guy has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/11/2026 | PBLS | $10.00M | +19.8% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| PBLS | ▲ Buy | Open Market | 375,000 | $7.5M | 6/11/2026 | View on chart |
| PBLS | ▲ Buy | Open Market | 125,000 | $2.5M | 6/11/2026 | View on chart |
| PBLS | ▼ Sell | Other | 527,070 | $5.0M | 6/11/2026 | View on chart |
| BCAB | ▲ Buy | Grant | 267,900 | $7.5M | 9/30/2021 | View on chart |
| BCAB | ▼ Sell | Open Market | 207,640 | $8.2M | 8/24/2021 | View on chart |
| BCAB | ▼ Sell | Open Market | 285,874 | $11.3M | 8/24/2021 | View on chart |
| BCAB | ▼ Sell | Open Market | 53,195 | $2.1M | 8/24/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Parabilis Medicines starts dose‑ranging cohort of Zolucatetide trial
Parabilis Medicines has begun a dose‑ranging cohort of its Zolucatetide program in patients with familial adenomatous polyposis, extending its Phase 1/2 clinical study. The new cohort will provide additional safety and efficacy data to help define the optimal dose for this indication. This development comes as the stock trades near a well‑tested support level and analysts maintain a target price near the top of its 52‑week range.
Parabilis Medicines starts dose‑ranging cohort of Zolucatetide trial. Parabilis Medicines has begun a dose‑ranging cohort of its Zolucatetide program in patients with familial adenomatous polyposis, extending its Phase 1/2 clinical study. The new cohort will provide additional safety and efficacy data to help define the optimal dose for this indication. This development comes as the stock trades near a well‑tested support level and analysts maintain a target price near the top of its 52‑week range.